Harbor Capital Advisors, Inc. Iovance Biotherapeutics, Inc. Transaction History

Harbor Capital Advisors, Inc.

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 13, 2024	BUY	$7.59 - $17.47 $133,083 - $306,318	17,534 Added 24.11%	90,267 $1.34 Million
Q4 2023 Jan 08, 2024	BUY	$3.3 - $8.89 $25,971 - $69,964	7,870 Added 12.13%	72,733 $591,000
Q3 2023 Oct 20, 2023	BUY	$4.44 - $8.79 $37,837 - $74,908	8,522 Added 15.13%	64,863 $295,000
Q2 2023 Jul 11, 2023	BUY	$5.36 - $9.06 $27,721 - $46,858	5,172 Added 10.11%	56,341 $396,000
Q1 2023 Apr 26, 2023	BUY	$5.53 - $8.22 $80,450 - $119,584	14,548 Added 39.73%	51,169 $312,000
Q4 2022 Jan 20, 2023	SELL	$5.62 - $10.0 $4,383 - $7,800	-780 Reduced 2.09%	36,621 $0
Q3 2022 Oct 28, 2022	SELL	$9.53 - $13.11 $19,374 - $26,652	-2,033 Reduced 5.16%	37,401 $358,000
Q2 2022 Jul 26, 2022	SELL	$6.38 - $18.33 $17,538 - $50,389	-2,749 Reduced 6.52%	39,434 $435,000
Q1 2022 Apr 28, 2022	SELL	$12.38 - $19.1 $115,839 - $178,718	-9,357 Reduced 18.15%	42,183 $702,000
Q4 2021 Feb 04, 2022	BUY	$16.55 - $27.63 $852,987 - $1.42 Million	51,540 New	51,540 $984,000

314

241M

3.77M

1.7M

Ticker IOVA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 157,800,992
Market Cap $1.46B
Description
Iovance Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells. It has six ongoing phase 2 clinical studies, including C-144-01, of its lead product candidate, lifileucel, for the treatment o...

Get notified when there are updates to the investment portfolio of Harbor Capital Advisors, Inc., based on Form 13F filings with the SEC.

Stay updated on Harbor Capital Advisors, Inc. with notifications on news.